Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Aoki, CA

Debora E. Aoki, Oakland, CA US

Patent application numberDescriptionPublished
20100121649METHODS AND SYSTEMS FOR USER REGISTRATION - A method and a system to register a user include using some user information stored and provided by a third party system. For example, the user may provide an identifier associated with the third party system. The identifier may be used to retrieve the user information. The user information may be used to at least partially complete the user registration.05-13-2010

Ichiri Aoki, San Clemente, CA US

Patent application numberDescriptionPublished
20120001692ADAPTIVE POWER AMPLIFIER - Reconfigurable distributed active transformers are provided. The exemplary embodiments provided allow changing of the effective number and configuration of the primary and secondary windings, where the distributed active transformer structures can be reconfigured dynamically to control the output power levels, allow operation at multiple frequency bands, maintain a high performance across multiple channels, and sustain desired characteristics across process, temperature and other environmental variations. Integration of the distributed active transformer power amplifiers and a low noise amplifier on a semiconductor substrate can also be provided.01-05-2012
20120176200CROSS-DIFFERENTIAL AMPLIFIER - A cross-differential amplifier is provided. The cross-differential amplifier includes an inductor connected to a direct current power source at a first terminal. A first and second switch, such as transistors, are connected to the inductor at a second terminal. A first and second amplifier are connected at their supply terminals to the first and second switch. The first and second switches are operated to commutate the inductor between the amplifiers so as to provide an amplified signal while limiting the ripple voltage on the inductor and thus limiting the maximum voltage imposed across the amplifiers and switches.07-12-2012

John M. Aoki, Cerritos, CA US

Patent application numberDescriptionPublished
20100145248SYSTEM FOR ENRICHING A BODILY FLUID WITH A GAS HAVING AUTOMATED PRIMING CAPABILITIES - This invention discloses a modular system having a base module, a mid-section control module, and a display module for preparing and administering a gas-enriched bodily fluid. Gas-enrichment is achieved by a gas-enriching device which can be in the form of a disposable cartridge. During operation, the gas-enrichment device is placed in an enclosure within the control module to form a fluid pathway for extracorporeal circulation of the bodily fluid. An electronic controller manages the various aspects of the system and executes an automated method for priming the extracorporeal circuit.06-10-2010
20100145249SYSTEM FOR ENRICHING A BODILY FLUID WITH A GAS HAVING A REMOVABLE GAS-ENRICHMENT DEVICE WITH AN INFORMATION RECORDING ELEMENT - This invention discloses a modular system having a base module, a mid-section control module, and a display module for preparing and administering a gas-enriched bodily fluid via an extracorporeal circuit. Gas-enrichment is achieved by a gas-enriching device which can be in the form of a disposable cartridge. The gas-enrichment device has an information recording element disposed thereon. During operation, the gas-enrichment device is placed in an enclosure within the control module. An electronic controller manages the various aspects of the system such as the production of gas-enriched fluid, flow rates, bubble detection, and automatic operation and shut down. The controller is capable of setting a fluid flow rate in the circuit according to a programming based on the information encoded in the information recording element.06-10-2010

Kei R. Aoki, Coto De Caza, CA US

Patent application numberDescriptionPublished
20080213796GFP-SNAP25 Fluorescence Release Assay for Botulinum Toxin Protease Activity - The present invention provides a nucleic acid molecule which contains a nucleotide sequence encoding a SNAP-25 substrate which includes (i) a green fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a portion of SNAP-25 that includes a BoNT/A, BoNT/C1 or BoNT/E recognition sequence containing a cleavage site, where the cleavage site intervenes between the green fluorescent protein and the first partner of the affinity couple. Further provided herein is a nucleic acid molecule which contains a nucleotide sequence encoding a tagged toxin substrate which includes (i) a fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a clostridial toxin recognition sequence containing a cleavage site, where the cleavage site intervenes between the fluorescent protein and the first partner of the affinity couple.09-04-2008

Patent applications by Kei R. Aoki, Coto De Caza, CA US

Kei Roger Aoki, Garden Grove, CA US

Patent application numberDescriptionPublished
20090317839BOTULINUM TOXIN SCREENING ASSAYS - Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.12-24-2009

Kei Roger Aoki, Coto De Caz, CA US

Patent application numberDescriptionPublished
20090004224ACTIVATABLE CLOSTRIDIAL TOXINS - Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.01-01-2009

Kei Roger Aoki, Caza, CA US

Patent application numberDescriptionPublished
20100055727FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TOXINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.03-04-2010

Kei Roger Aoki, Irvine, CA US

Patent application numberDescriptionPublished
20090035822Fusion Proteins - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.02-05-2009
20100247509Fusion Proteins - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.09-30-2010
20110027256FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.02-03-2011
20110091437FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.04-21-2011
20110177053NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.07-21-2011
20120058098NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.03-08-2012
20120064059FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acids encoding the fusion proteins, methods of preparing same and uses thereof are also described.03-15-2012
20120156186NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a galanin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are is also described.06-21-2012
20120189610TREATMENT OF PAIN - Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.07-26-2012

Patent applications by Kei Roger Aoki, Irvine, CA US

K. Roger Aoki, Laguna Hills, CA US

Patent application numberDescriptionPublished
20090318360Use of the neurotoxic component of a botulinum toxin for treating arthritis - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.12-24-2009

K. Roger Aoki, Irvine, CA US

Patent application numberDescriptionPublished
20100034802TREATMENT OF PAIN - Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.02-11-2010

Norihiro Edwin Aoki, Sunneyvale, CA US

Patent application numberDescriptionPublished
20100199347Method and Apparatus for Authenticating Usage of an Application - Methods and apparatuses, including computer program products, are described for authenticating the usage of an application. A request to execute an application is received from a user device. The application is executed based on the request. An application-level usage indicator is received from the user device. The application-level usage indicator corresponds to current operation of the application by a user and comprises at least (i) user input commands and (ii) passive usage metrics. The identity of the user is determined by comparing the application-level usage indicator with a pre-established user profile wherein the user profile is associated with previous operation of the application by the user and comprises at least (i) user input commands and (ii) passive usage metrics. Execution of the application is terminated at the user device if the identified user is not entitled to use the application according to the user profile.08-05-2010

Norihiro Edwin Aoki, Sunnyvale, CA US

Patent application numberDescriptionPublished
20120191553POINT OF SALE PAYMENT SYSTEM - A method for point of sale payments includes receiving, from a seller device over a network, payment information. The payment information is associated with payment code information in a database. The payment code information is then sent to the seller device over the network for posting at a service location. The payment code information is then captured by a payer device at the service location and transmitted over the network. The payment information is then retrieved from the database using the associated payment code information. The payment information is then sent to the payer device over the network. A payment confirmation is received from the payer device over the network and, in response, a payment from a payer account to a seller account is initiated and the payment information and an indication of the payment confirmation is sent to the seller device over the network.07-26-2012

Paul M. Aoki, Berkeley, CA US

Patent application numberDescriptionPublished
20090007236System And Method For Using A Communication Lease To Open A Communication Channel - A system and method for using a communication lease to open a communication channel is provided. An initiation terminal transmits a channel initiation request for access to a resource manager through a target terminal. Evaluation of a communication lease controlling access to the resource manager is awaited. Approval of the channel initiation request is received upon the successful evaluation of the communication lease. A communication channel is opened between the initiation terminal and the target terminal upon receipt of the approval.01-01-2009
20100057445System And Method For Automatically Adjusting Floor Controls For A Conversation - A system and method for automatically adjusting floor controls for a conversation is provided. Audio streams are received, which each originate from an audio source. Floor controls for a current configuration including at least a portion of the audio streams are maintained. Conversational characteristics shared by two or more of the audio sources are determined. Possible configurations for the audio streams are identified based on the conversational characteristics. An analysis of the current configuration and the possible configurations is performed. A change threshold is applied to the analysis. When the analysis satisfies the change threshold, the floor controls are automatically adjusted. The audio streams are mixed into one or more outputs based on the adjusted floor controls.03-04-2010
20100289730FOLDING ELECTRONIC DEVICE WITH CONTINUOUS DISPLAY - In general, in one aspect, the disclosure describes an apparatus that includes two panels pivotally connected together. The panels can pivot from an open arrangement where the two panels lay side by side to a closed arrangement where the two panels lay one on top of another. The apparatus also includes a flexible display connected to the two panels and having a portion that is mechanically free from the two panels. The apparatus further includes a cavity to receive at least a portion of the free portion of the display when the panels are pivoted into the closed arrangement.11-18-2010
20110018785SLIDE-OUT INFORMATION DISPLAY - Slide-out and roll-up information displays and methods supply enlarged viewing areas. A slide-out information display device includes stacked display segments wherein each of the display segments except one is at least partially covered by the others. Separable bezel segments support the display segments, the stacked display segments being uncovered when the bezel segments are separated from a collapsed configuration to an un-collapsed configuration for use by a user. A roll-up display device includes flexible display membranes. Scrolling assemblies in the roll-up display include rotatably mounted scrolling assembly mechanisms for rolling up the flexible display membranes. Some scrolling assemblies are movable and can be extended beyond the housing members. At least one display membrane being covered by at least one other display membrane when the movable scrolling assemblies are not extended, and the covered display membranes being uncovered when the movable scrolling assemblies are extended.01-27-2011
20110037827System And Method For Coordinating Data Transmission Via User-Maintained Modes - A method and apparatus for controlling data transmission via user-maintained modes is provided. A first audio data stream is recorded on a transmitting electronic apparatus. A second audio data stream is stored on the transmitting electronic apparatus. Transmission of one of the first and the second audio data streams is controlled via a first user-maintained mode when at least the other of the first and the second audio data streams is being transmitted to the electronic apparatus. The one of the first and the second audio data streams is transmitted to a receiving electronic apparatus and the other of the first and the second audio data streams is suspended.02-17-2011
20120158402System And Method For Adjusting Floor Controls Based On Conversational Characteristics Of Participants - A system and method for automatically adjusting floor controls based on conversational characteristics is provided. Audio streams are received, which each originate from an audio source. Floor controls for a current configuration including at least a portion of the audio streams are maintained. Conversational characteristics shared by two or more of the audio sources are determined. Possible configurations for the audio streams are identified based on the conversational characteristics. An analysis of the current configuration and the possible configurations is performed. A change threshold comprising a minimum number of timeslices for at least one of the current configuration and one of the possible configurations is applied to the analysis. When the analysis satisfies the change threshold, the floor controls are automatically adjusted. The audio streams are mixed into one or more outputs based on the adjusted floor controls.06-21-2012
20120162049FOLDING ELECTRONIC DEVICEWITH CONTINUOUS DISPLAY - In general, in one aspect, the disclosure describes an apparatus that includes two panels pivotally connected together. The panels can pivot from an open arrangement where the two panels lay side by side to a closed arrangement where the two panels lay one on top of another. The apparatus also includes a flexible display connected to the two panels and having a portion that is mechanically free from the two panels. The apparatus further includes a cavity to receive at least a portion of the free portion of the display when the panels are pivoted into the closed arrangement.06-28-2012

Patent applications by Paul M. Aoki, Berkeley, CA US

Paul Masami Aoki, Berkeley, CA US

Patent application numberDescriptionPublished
20090313553System And Method For Providing Multimedia Content Between A Plurality Of User Terminals - A system and method for providing multimedia content between a plurality of user terminals is presented. A first multimedia presentation on a first user terminal is selected by a first user. Data corresponding to the first multimedia presentation is transmitted to a second user terminal. Data is received corresponding to a second multimedia presentation from the second user terminal by the first user terminal. The first multimedia presentation or the second multimedia presentation is displayed on the first user terminal and the second user terminal based on, respectively, a first profile of the first user terminal and a second profile of the second user terminal.12-17-2009

Roger K. Aoki, Irvine, CA US

Patent application numberDescriptionPublished
20090162341Non-Cytotoxic Protein Conjugates - A non-cytotoxic protein conjugate for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell, comprising: (i) a Targeting Moiety (TM), wherein said TM is an agonist of a receptor present on said nociceptive sensory afferent cell, and wherein said receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of said nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.06-25-2009

Roger K. Aoki, Coto De Caza, CA US

Patent application numberDescriptionPublished
20120141532 Botulinum Toxin Formulation - Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.06-07-2012

Stephanie Aoki, Goleta, CA US

Patent application numberDescriptionPublished
20080317762Bacterial Contact Inhibition and Methods Therefor - Contemplated compositions and methods relate to bacterial contact inhibition that is conferred by two gene products, CdiA and CdiB, which are encoded by the genes cdiA and cdiB, respectively. A further gene product CdiI, encoded by the gene cdiI confers immunity to contact inhibition caused by CdiAB.12-25-2008